SCHEMBL4134009

SCHEMBL4134009

O=C(NC1CCCC1O)c1[nH]c2ncc(NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)cc2c1-c1ccc2c(c1)OCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.41
KDM4E B2RXH2 1/20 0.38
HTR6 P50406 3/20 0.38
ALDH1A1 P00352 2/20 0.37
MAPT P10636 3/20 0.37
PKM P14618 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ABL1 P00519 1/20 0.37
SERPINE1 P05121 1/20 0.36
KIT P10721 2/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4134010 1.00 CNR1 (0.41) CNR1KDM4EHTR6ALDH1A1MAPT
SCHEMBL4139283 0.88 KIT (0.39) KDM4EHTR6ALDH1A1MAPTPKM
SCHEMBL4139287 0.88 KIT (0.39) KDM4EHTR6ALDH1A1MAPTPKM
SCHEMBL4138419 0.88 SERPINE1 (0.45) CNR1HTR6MAPTABL1SERPINE1
SCHEMBL4138421 0.88 SERPINE1 (0.45) CNR1HTR6MAPTABL1SERPINE1
SCHEMBL4139293 0.87 CNR1 (0.41) CNR1HTR6MAPTSERPINE1KIT
SCHEMBL4139291 0.87 CNR1 (0.41) CNR1HTR6MAPTSERPINE1KIT
SCHEMBL4133870 0.86 CNR1 (0.41) CNR1HTR6MAPTSERPINE1KIT
SCHEMBL4133869 0.86 CNR1 (0.41) CNR1HTR6MAPTSERPINE1KIT
SCHEMBL4135800 0.84 CNR1 (0.39) CNR1HTR6MAPTSERPINE1KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AG (DE) 2009-04-16 US claimed
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AG (DE) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY5, ADCY2 CNR1 1177/4885KDM4E 2032/4885HTR6 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.